Ceftibuten

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ceftibuten
Ceftibuten-Formulae.png
Clinical data
Trade names Cedax
AHFS/Drugs.com Monograph
MedlinePlus a698023
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.238.211
Chemical and physical data
Formula C15H14N4O6S2
Molar mass 410.427 g.mol−1
3D model (Jmol)
  (verify)

Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally administered agent, with two dosage forms, capsule or oral suspension. It is marketed by Pernix Therapeutics under the trade name Cedax.

Medical uses[edit]

Main article: Cephalosporin

Ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis. It is also indicated for pneumonia, infections of the urinary tract, enteritis, and gastroenteritis.[citation needed]

Ceftibuten is available in as capsules and as a powder for oral suspension.

Adverse effects[edit]

In 3,000 patients, ceftibuten was well tolerated. The most frequent reactions were gastrointestinal and nausea.

Spectrum of susceptibility[edit]

Ceftibuten is active against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Proteus vulgaris, P. mirabilis, P. providence, Salmonella sp., Shigella sp., Enterobacter sp., and Streptococcus sp.

The following represents minimum inhibitory concentration (MIC) susceptibility data for a few clinically significant microorganisms:

  • Haemophilus influenzae: 0.015–1.0 µg/ml
  • Moraxella catarrhalis: 0.5–4.0  µg/ml
  • Streptococcus pneumoniae: 0.5–256 µg/ml [1]

References[edit]

External links[edit]